UTAA91 injection for autoimmune diseases that did not get better with standard treatment
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Immune system & allergy, Skin clinical trials.
This study tests a new injection, UTAA91, for people with certain autoimmune diseases that have come back or not responded to standard therapy. It aims to see if the treatment is safe and helpful for conditions like rheumatoid arthritis, lupus, or scleroderma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- Your autoimmune disease (like lupus, rheumatoid arthritis, scleroderma, or similar) must have come back or not improved with standard treatment
- You must be expected to live at least 3 more months
- Your liver, kidneys, heart, and lungs must be working well enough
- You must not have had another cancer in the last 5 years
- You must not have active infections, serious heart problems, or be pregnant or planning pregnancy within 2 years after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases like lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. It's for those whose disease hasn't improved with standard treatments.
This study tests a new investigational drug (called ATG-201) for people with autoimmune diseases. It aims to see if the drug is safe and how it works in the body.
This trial tests an experimental cell therapy (GT719) for people with autoimmune diseases like lupus, inflammatory myositis, or systemic sclerosis that have not responded well to other treatments. It aims to see if this therapy can help control the disease.
This trial tests if a new cell therapy called GT719 can help people with moderate to severe lupus, inflammatory myopathy, or systemic sclerosis that hasn't gotten better with standard treatments. It aims to find a new option for those who have not responded well to usual medications.
This early-stage study tests a new cell-based treatment called GT801 for autoimmune diseases that haven't responded well to standard medicines. It aims to see if this approach is safe and helps reduce symptoms in conditions like lupus, vasculitis, and scleroderma.
This trial tests a new injection called UTAA91 for people with hard-to-treat rheumatoid arthritis. It's for those who have tried standard treatments without success.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.